This “Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complicated skin and soft tissue infections (cSSTI) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Complicated skin and soft tissue infections (cSSTI): Overview
Skin and soft tissue infections (SSTIs) refer to a wide clinical spectrum of common infectious diseases that often require acute treatment and inpatient hospital admission. Complicated SSTIs (cSSTIs) are the most severe, involving deeper soft tissues and include infective cellulitis, ulcer or wound site infections, surgical site infections, major abscesses, infected burns, skin ulcers, and diabetic foot ulcers. Staphylococcus aureus is the commonest cause of cSSTIs. The management of cSSTIs normally involves a combination of surgical procedures and antibiotic therapy. The main choice of antibiotic depends on the clinical presentation.
"Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complicated skin and soft tissue infections (cSSTI) pipeline landscape is provided which includes the disease overview and Complicated skin and soft tissue infections (cSSTI) treatment guidelines. The assessment part of the report embraces, in depth Complicated skin and soft tissue infections (cSSTI) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complicated skin and soft tissue infections (cSSTI) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Complicated skin and soft tissue infections (cSSTI) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Complicated skin and soft tissue infections (cSSTI) Emerging Drugs
Complicated skin and soft tissue infections (cSSTI): Therapeutic Assessment
This segment of the report provides insights about the different Complicated skin and soft tissue infections (cSSTI) drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Complicated skin and soft tissue infections (cSSTI)
There are approx. 5+ key companies which are developing the therapies for Complicated skin and soft tissue infections (cSSTI). The companies which have their Complicated skin and soft tissue infections (cSSTI) drug candidates in the mid to advanced stage, i.e. phase III include, Baselia pharmaceutica and others.
The report covers around 5+ products under different phases of clinical development like
Complicated skin and soft tissue infections (cSSTI) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Complicated skin and soft tissue infections (cSSTI): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complicated skin and soft tissue infections (cSSTI) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complicated skin and soft tissue infections (cSSTI) drugs.
Complicated skin and soft tissue infections (cSSTI) Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Complicated skin and soft tissue infections (cSSTI): Overview
Skin and soft tissue infections (SSTIs) refer to a wide clinical spectrum of common infectious diseases that often require acute treatment and inpatient hospital admission. Complicated SSTIs (cSSTIs) are the most severe, involving deeper soft tissues and include infective cellulitis, ulcer or wound site infections, surgical site infections, major abscesses, infected burns, skin ulcers, and diabetic foot ulcers. Staphylococcus aureus is the commonest cause of cSSTIs. The management of cSSTIs normally involves a combination of surgical procedures and antibiotic therapy. The main choice of antibiotic depends on the clinical presentation.
"Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complicated skin and soft tissue infections (cSSTI) pipeline landscape is provided which includes the disease overview and Complicated skin and soft tissue infections (cSSTI) treatment guidelines. The assessment part of the report embraces, in depth Complicated skin and soft tissue infections (cSSTI) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complicated skin and soft tissue infections (cSSTI) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Complicated skin and soft tissue infections (cSSTI) R&D. The therapies under development are focused on novel approaches to treat/improve Complicated skin and soft tissue infections (cSSTI).
This segment of the Complicated skin and soft tissue infections (cSSTI) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Complicated skin and soft tissue infections (cSSTI) Emerging Drugs
- Contezolid (MRX-I): MicuRx Pharmaceuticals Inc.
- Ceftobiprole medocaril: Basilea Pharmaceutica
Complicated skin and soft tissue infections (cSSTI): Therapeutic Assessment
This segment of the report provides insights about the different Complicated skin and soft tissue infections (cSSTI) drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Complicated skin and soft tissue infections (cSSTI)
There are approx. 5+ key companies which are developing the therapies for Complicated skin and soft tissue infections (cSSTI). The companies which have their Complicated skin and soft tissue infections (cSSTI) drug candidates in the mid to advanced stage, i.e. phase III include, Baselia pharmaceutica and others.
The report covers around 5+ products under different phases of clinical development like
- Late-stage products (phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Complicated skin and soft tissue infections (cSSTI) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Complicated skin and soft tissue infections (cSSTI): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complicated skin and soft tissue infections (cSSTI) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complicated skin and soft tissue infections (cSSTI) drugs.
Complicated skin and soft tissue infections (cSSTI) Report Insights
- Complicated skin and soft tissue infections (cSSTI) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Complicated skin and soft tissue infections (cSSTI) drugs?
- How many Complicated skin and soft tissue infections (cSSTI) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complicated skin and soft tissue infections (cSSTI)?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Complicated skin and soft tissue infections (cSSTI) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Complicated skin and soft tissue infections (cSSTI) and their status?
- What are the key designations that have been granted to the emerging drugs?
- MicuRx Pharmaceuticals Inc.
- Basilea pharmaceutica
- MRX-I
- Ceftobiprole medocaril
Note: Product cover images may vary from those shown
Introduction
Executive Summary
Complicated skin and soft tissue infections (cSSTI): Overview
In-depth Commercial Assessment
Complicated skin and soft tissue infections (cSSTI) Key Products
Complicated skin and soft tissue infections (cSSTI) - Unmet Needs
Complicated skin and soft tissue infections (cSSTI) - Market Drivers and Barriers
Complicated skin and soft tissue infections (cSSTI) - Future Perspectives and Conclusion
Complicated skin and soft tissue infections (cSSTI) Analyst Views
Complicated skin and soft tissue infections (cSSTI) Key Companies
Appendix
List of Tables
Table 1 Total Products for Complicated skin and soft tissue infections (cSSTI)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Complicated skin and soft tissue infections (cSSTI)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Executive Summary
Complicated skin and soft tissue infections (cSSTI): Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
In-depth Commercial Assessment
- Complicated skin and soft tissue infections (cSSTI) companies' collaborations, Licensing, Acquisition - Deal Value Trends
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
Complicated skin and soft tissue infections (cSSTI) Key Products
Complicated skin and soft tissue infections (cSSTI) - Unmet Needs
Complicated skin and soft tissue infections (cSSTI) - Market Drivers and Barriers
Complicated skin and soft tissue infections (cSSTI) - Future Perspectives and Conclusion
Complicated skin and soft tissue infections (cSSTI) Analyst Views
Complicated skin and soft tissue infections (cSSTI) Key Companies
Appendix
List of Tables
Table 1 Total Products for Complicated skin and soft tissue infections (cSSTI)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Complicated skin and soft tissue infections (cSSTI)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
- MicuRx Pharmaceuticals Inc.
- Basilea pharmaceutica
Note: Product cover images may vary from those shown